Skip to main content
. 2018 May 16;11:2891–2899. doi: 10.2147/OTT.S165840

Figure 3.

Figure 3

BCG and anti-PD-L1 combination therapy inhibited tumor progression and prolonged survival in the orthotopic rat BCa model.

Notes: (A) Study design: orthotopic rat BCa models received intravesical BCG instillation (500 μg) every week for four doses and/or 200 μg anti-PD-L1 (clone 10F.9G2) or isotype control i.p. every 4 days for a total of seven times (n=10 animals per group). Tumor weight (B) and survival percentage (C) were monitored and measured at the endpoint (animal death date or day 60). *P<0.01; **P<0.05.

Abbreviations: BCG, Bacillus Calmette–Guérin; i.p., intraperitoneal injection; PD-L1, programmed death-ligand 1.